Christoph Sarrazin

List of Publications by Year
in descending order

233 papers	18,928 citations	17440 63 h-index	12272 133 g-index
248 all docs	248 docs citations	248 times ranked	15387 citing authors

#	Article	IF	Citations
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619
2	Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis. Gastroenterology, 2008, 134, 960-974.e8.	1.3	1,314
3	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241
4	Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor Telaprevir. Gastroenterology, 2007, 132, 1767-1777.	1.3	602
5	Liver Fibrosis in Viral Hepatitis: Noninvasive Assessment with Acoustic Radiation Force Impulse Imaging versus Transient Elastography. Radiology, 2009, 252, 595-604.	7.3	601
6	Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. Gastroenterology, 2006, 130, 1086-1097.	1.3	500
7	Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 447-462.	1.3	489
8	A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nature Genetics, 2015, 47, 1443-1448.	21.4	435
9	Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2. Journal of Hepatology, 2004, 40, 993-999.	3.7	391
10	The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. Journal of Hepatology, 2016, 64, 486-504.	3.7	389
11	Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology, 2007, 46, 631-639.	7.3	378
12	SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon Î±-2b for Genotype 1 Nonresponders. Gastroenterology, 2007, 132, 1270-1278.	1.3	307
13	Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology, 2010, 51, 73-80.	7.3	303
14	Real-Time Elastography for Noninvasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis. American Journal of Roentgenology, 2007, 188, 758-764.	2.2	301
15	Treatment predictors of a sustained virologic response in hepatitis B and C. Journal of Hepatology, 2008, 49, 634-651.	3.7	290
16	Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology, 2009, 50, 1709-1718.	7.3	282
17	Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology, 2006, 44, 318-325.	7.3	278
18	Antiviral strategies in hepatitis C virus infection. Journal of Hepatology, 2012, 56, S88-S100.	3.7	261

#	Article	IF	Citations
19	Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology, 2011, 53, 86-95.	7.3	252
20	Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. Hepatology, 2003, 37, 600-609.	7.3	247
21	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. The Lancet Gastroenterology and Hepatology, 2022, 7, 396-415.	8.1	237
22	Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology, 2009, 50, 2001-2006.	7.3	228
23	Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. Journal of Hepatology, 2011, 54, 887-893.	3.7	226
24	Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. Journal of Hepatology, 2011, 54, 415-421.	3.7	202
25	Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir andÂSofosbuvir. Gastroenterology, 2016, 151, 501-512.e1.	1.3	192
26	Serum miR-122 as a Biomarker of Necroinflammation in Patients With Chronic Hepatitis C Virus Infection. American Journal of Gastroenterology, 2011, 106, 1663-1669.	0.4	171
27	Acoustic Radiation Force Impulse Elastography for fibrosis evaluation in patients with chronic hepatitis C: An international multicenter study. European Journal of Radiology, 2012, 81, 4112-4118.	2.6	156
28	Viral Determinants of Resistance to Treatment in Patients with Hepatitis C. Clinical Microbiology Reviews, 2007, 20, 23-38.	13.6	142
29	Patterns of Resistance-Associated Substitutions in Patients WithÂChronic HCV Infection Following Treatment With Direct-Acting Antivirals. Gastroenterology, 2018, 154, 976-988.e4.	1.3	132
30	Detection of Residual Hepatitis C Virus RNA by Transcription-Mediated Amplification in Patients With Complete Virologic Response According to Polymerase Chain Reactionâ€“Based Assays. Hepatology, 2000, 32, 818-823.	7.3	127
31	Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e26971.	2.5	120
32	Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterology, 2010, 10, 103.	2.0	117
33	Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas) Tj ETQq1 1 0.784314 rgBT /O and Quantification. Journal of Clinical Microbiology, 2008, 46, 3880-3891.	3.9	115
34	Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology, 2010, 51, 1127-1136.	7.3	115
35	Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. Journal of Hepatology, 2011, 55, 322-327.	3.7	115
36	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. Journal of Hepatology, 2012, 56, 520-526.	3.7	114

#	Article	IF	Citations
37	Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology, 2013, 58, 1270-1276.	7.3	114
38	Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. Journal of Clinical Virology, 2011, 52, 321-327.	3.1	110
39	The role of resistance in HCV treatment. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 487-503.	2.4	108
40	Mutations in the Protein Kinaseâ€"Binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a Are Associated with Treatment Response. Journal of Infectious Diseases, 2000, 181, 432-441.	4.0	106
41	Benefit of a clipping device in use in intestinal bleeding and intestinal leakage. Gastrointestinal Endoscopy, 2011, 74, 389-397.	1.0	103
42	Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Research, 2015, 116, 10-16.	4.1	103
43	Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells. PLoS Pathogens, 2011, 7, e1002045.	4.7	102
44	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut, 2019, 68, 1099-1107.	12.1	100
45	Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5. Journal of Clinical Microbiology, 2006, 44, 729-737.	3.9	94
46	Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. Journal of Clinical Virology, 2002, 25, 23-29.	3.1	93
47	Multi-center evaluation of the Abbott RealTime HCV Assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. Journal of Clinical Virology, 2011, 52, 133-137.	3.1	90
48	Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients. Journal of Virology, 2013, 87, 6172-6181.	3.4	88
49	Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Markers. Journal of Clinical Gastroenterology, 2010, 44, 58-65.	2.2	87
50	Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?. Antiviral Research, 2014, 105, 64-71.	4.1	85
51	Assessment of Liver Fibrosis with 2-D Shear Wave Elastography in Comparison to Transient Elastography and Acoustic Radiation Force Impulse Imaging in Patients with Chronic Liver Disease. Ultrasound in Medicine and Biology, 2015, 41, 2350-2359.	1.5	83
52	Mutagenic Effect of Ribavirin on Hepatitis C Nonstructural 5B Quasispecies In Vitro and During Antiviral Therapy. Gastroenterology, 2007, 132, 921-930.	1.3	79
53	Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity. PLoS ONE, 2012, 7, e30796.	2.5	78
54	Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. Journal of Hepatology, 1999, 30, 1004-1013.	3.7	77

#	Article	IF	Citations
55	Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver International, 2008, 28, 1332-1343.	3.9	77
56	The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. Digestive and Liver Disease, 2013, 45, 762-768.	0.9	76
57	Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis. Liver International, 2012, 32, 852-858.	3.9	75
58	Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology, 2012, 55, 1700-1710.	7.3	75
59	Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biology, 2008, 9, R16.	9.6	74
60	Future treatment of chronic hepatitis <scp>C</scp> with direct acting antivirals: is resistance important?. Liver International, 2012, 32, 79-87.	3.9	73
61	A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants. PLoS Computational Biology, 2010, 6, e1000745.	3.2	69
62	Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. Journal of Hepatology, 1998, 29, 29-35.	3.7	67
63	Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients. PLoS ONE, 2015, 10, e0134395.	2.5	67
64	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. Journal of Hepatology, 2016, 65, 473-482.	3.7	64
65	Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology, 2010, 52, 1201-1207.	7.3	63
66	Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. Journal of Hepatology, 2016, 64, 790-799.	3.7	63
67	Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology, 2000, 31, 1360-1370.	7.3	62
68	Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses. Journal of Virology, 2002, 76, 11079-11090.	3.4	62
69	A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C. PLoS ONE, 2012, 7, e40159.	2.5	60
70	Second-Generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for Viral Load Monitoring: a Novel Dual-Probe Assay Design. Journal of Clinical Microbiology, 2013, 51, 571-577.	3.9	60
71	Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. Journal of Hepatology, 2004, 41, 652-658.	3.7	56
72	Treatment failure with DAA therapy: Importance of resistance. Journal of Hepatology, 2021, 74, 1472-1482.	3.7	55

#	Article	IF	Citations
73	Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprepâ„¢/COBAS) Tj ETQq1 1 0.784314 rgBT /Over	3.1	54
74	Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology, 2009, 50, 369-377.	7.3	53
75	Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen. Antiviral Therapy, 2018, 23, 211-217.	1.0	53
76	Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. Journal of Hepatology, 2019, 71, 889-899.	3.7	52
77	Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon Î± for chronic hepatitis C. Journal of Hepatology, 2003, 39, 106-111.	3.7	51
78	Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. Journal of Hepatology, 2010, 52, 832-838.	3.7	50
79	Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. Human Molecular Genetics, 2014, 23, 3883-3890.	2.9	50
80	Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 1012-1020.	2.4	50
81	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. Journal of Hepatology, 2015, 62, 31-40.	3.7	50
82	Interferon lambda 4 genotypes and resistanceâ€associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology, 2016, 63, 63-73.	7.3	50
83	No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12â€weeks in HCV DAA-experienced patients. Journal of Hepatology, 2018, 69, 1221-1230.	3.7	50
84	Hepatitis C virus-related resistance mechanisms to interferon Î±-based antiviral therapy. Journal of Clinical Virology, 2005, 32, 86-91.	3.1	47
85	Assessment, by Transcription-Mediated Amplification, of Virologic Response in Patients with Chronic Hepatitis C Virus Treated with Peginterferon Î±-2a. Journal of Clinical Microbiology, 2001, 39, 2850-2855.	3.9	46
86	Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue. Journal of Clinical Virology, 2005, 32, 289-293.	3.1	46
87	Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology, 2019, 70, 771-787.	7.3	46
88	High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. PLoS ONE, 2012, 7, e41206.	2.5	43
89	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. The Lancet Gastroenterology and Hepatology, 2018, 3, 856-864.	8.1	43
90	Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24â€“72 Weeks. Gastroenterology, 2011, 141, 1656-1664.	1.3	40

#	Article	IF	Citations
91	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. Journal of Virology, 2011, 85, 7613-7621.	3.4	40
92	Quasispecies Heterogeneity of the Carboxy-Terminal Part of the E2 Gene Including the PePHD and Sensitivity of Hepatitis C Virus 1b Isolates to Antiviral Therapy. Virology, 2001, 289, 150-163.	2.4	39
93	New hepatitis C therapies in clinical development. European Journal of Medical Research, 2011, 16, 303.	2.2	39
94	Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. Journal of Clinical Virology, 2012, 55, 17-22.	3.1	39
95	Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. Journal of Hepatology, 2014, 60, 913-919.	3.7	39
96	Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. Journal of Virological Methods, 2015, 214, 29-32.	2.1	39
97	Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. Hepatology, 2004, 39, 1456-1457.	7.3	37
98	Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection. Hepatology, 2015, 61, 812-822.	7.3	37
99	Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. Journal of Hepatology, 2017, 67, 680-686.	3.7	37
100	Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver International, 2017, 37, 205-211.	3.9	37
101	Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients. Journal of Infectious Diseases, 2018, 218, 114-123.	4.0	37
102	Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis. Journal of Hepatology, 2014, 61, 1247-1252.	3.7	36
103	Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C. Antiviral Therapy, 2006, 11, 507-519.	1.0	35
104	Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical Gastroenterology and Hepatology, 2010, 8, 884-890.	4.4	33
105	Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level. Journal of Hepatology, 2015, 62, 791-798.	3.7	33
106	Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology, 2003, 38, 1592-1592.	7.3	32
107	Long-term follow-up of endoscopic therapy for stenosis of the biliobiliary anastomosis associated with orthotopic liver transplantation. Liver Transplantation, 2013, 19, 586-593.	2.4	32
108	HCV RNA Quantification with Different Assays: Implications for Protease-Inhibitor-Based Response-Guided Therapy. Antiviral Therapy, 2014, 19, 559-567.	1.0	32

#	Article	IF	Citations
109	HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. Journal of Virological Methods, 2017, 245, 14-18.	2.1	32
110	Development of a Second Version of the Cobas AmpliPrep/Cobas TaqMan Hepatitis C Virus Quantitative Test with Improved Genotype Inclusivity. Journal of Clinical Microbiology, 2011, 49, 3309-3315.	3.9	30
111	Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication. Gastroenterology, 2012, 143, 439-447.e1.	1.3	30
112	Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. Journal of Hepatology, 2000, 33, 640-647.	3.7	29
113	Structural and functional comparison of the non-structural protein 4B in flaviviridae. Journal of Molecular Graphics and Modelling, 2007, 26, 546-557.	2.4	29
114	Apolipoprotein E allele frequencies in chronic and selfâ€limited hepatitis C suggest a protective effect of <scp>APOE</scp>4 in the course of hepatitis C virus infection. Liver International, 2016, 36, 1267-1274.	3.9	29
115	Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals. Liver Cancer, 2018, 7, 190-204.	7.7	28
116	Prevalence and clinical and histological manifestation of hepatitis G/GBV-C infections in patients with elevated aminotransferases of unknown etiology. Journal of Hepatology, 1997, 27, 276-283.	3.7	27
117	GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. Journal of Hepatology, 2005, 43, 388-393.	3.7	27
118	Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. Journal of Hepatology, 2004, 40, 845-852.	3.7	26
119	Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-Î±-2a and ribavirin. European Journal of Gastroenterology and Hepatology, 2010, 22, 1303-1307.	1.6	26
120	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. Journal of Hepatology, 2017, 67, 237-245.	3.7	26
121	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 2021, 74, 801-810.	3.7	26
122	Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061. Antiviral Therapy, 2006, 11, 371-376.	1.0	26
123	HLA-Bâˆ—27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope. Journal of Hepatology, 2014, 60, 22-29.	3.7	24
124	Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. Gut, 2017, 66, 1829-1837.	12.1	24
125	Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving directâ€acting antiviral therapyâ€"Results from the German Hepatitis Câ€Registry. Journal of Viral Hepatitis, 2020, 27, 690-698.	2.0	24
126	Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX) Tj ETQq0 0 0 rgBT /Overlock 10 T Biomedical and Life Sciences, 2009, 877, 4001-4006.	2.3	23

#	Article	IF	Citations
127	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. Clinical Infectious Diseases, 2016, 62, 1228-1234.	5.8	23
128	Treatment of hepatitis C genotype 1Âinfection in Germany: effectiveness and safety of antiviral treatment in a realâ€world setting. United European Gastroenterology Journal, 2018, 6, 213-224.	3.8	22
129	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon-Î±2b therapy for Acute Hepatitis C. Antiviral Therapy, 2007, 12, 303-316.	1.0	22
130	Clinical Significance of In Vitro Replicationâ€“Enhancing Mutations of the Hepatitis C Virus (HCV) Replicon in Patients with Chronic HCV Infection. Journal of Infectious Diseases, 2005, 192, 1710-1719.	4.0	21
131	Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antiviral Therapy, 2010, 15, 1099-1106.	1.0	21
132	The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. Journal of Gastroenterology, 2011, 46, 1427-1436.	5.1	21
133	Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C. PLoS ONE, 2014, 9, e112592.	2.5	20
134	Current Standards in the Treatment of Chronic Hepatitis C. Deutsches Ärzteblatt International, 2012, 109, 352-8.	0.9	20
135	Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C. Antiviral Therapy, 2006, 11, 507-19.	1.0	20
136	How to use virological tools for the optimal management of chronic hepatitis C. Liver International, 2011, 31, 3-12.	3.9	19
137	Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients. PLoS ONE, 2014, 9, e87974.	2.5	19
138	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. Journal of Hepatology, 2015, 62, 1246-1255.	3.7	19
139	Clinical significance of detectable and quantifiable <scp>HCV RNA</scp> at the end of treatment with ledipasvir/sofosbuvir in <scp>GT</scp>1 patients. Liver International, 2018, 38, 1906-1910.	3.9	18
140	Association of HCV-related mixed cryoglobulinemia with specific mutational pattern of the HCV E2 protein and CD81 expression on peripheral B lymphocytes. Blood, 2004, 104, 1228-1229.	1.4	17
141	HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals. Antiviral Therapy, 2015, 20, 177-183.	1.0	17
142	Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response. Liver International, 2019, 39, 2174-2183.	3.9	17
143	PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C. PLoS ONE, 2014, 9, e94512.	2.5	17
144	Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061. Antiviral Therapy, 2006, 11, 371-6.	1.0	17

#	Article	IF	Citations
145	Mutations within the CD81â€Binding Sites and Hypervariable Region 2 of the Envelope 2 Protein: Correlation with Treatment Response in Hepatitis C Virusâ€"Infected Patients. Journal of Infectious Diseases, 2003, 187, 982-987.	4.0	16
146	Characterization of the inhibition of hepatitis C virus entry byIn vitro-generated and patient-derived oxidized low-density lipoprotein. Hepatology, 2013, 57, 1716-1724.	7.3	16
147	Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels. International Journal of Molecular Sciences, 2016, 17, 922.	4.1	16
148	Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. Journal of Clinical Microbiology, 2017, 55, 1131-1139.	3.9	15
149	Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis. PLoS ONE, 2014, 9, e110857.	2.5	15
150	The importance of HCV RNA measurement for tailoring treatment duration. Digestive and Liver Disease, 2013, 45, S323-S331.	0.9	14
151	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. Journal of Viral Hepatitis, 2022, 29, 536-542.	2.0	14
152	Current therapy for hepatitis C. International Journal of Colorectal Disease, 2007, 22, 341-349.	2.2	13
153	Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B. Journal of Clinical Virology, 2011, 52, 204-209.	3.1	13
154	An OPTIMIZE Study Retrospective Analysis for Management of Telaprevir-Treated Hepatitis C Virus (HCV)-Infected Patients by Use of the Abbott RealTi m e HCV RNA Assay. Journal of Clinical Microbiology, 2015, 53, 1264-1269.	3.9	13
155	Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir. Antimicrobial Agents and Chemotherapy, 2015, 59, 2746-2755.	3.2	13
156	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. Journal of Antimicrobial Chemotherapy, 2020, 75, 3349-3358.	3.0	13
157	Prospective follow-up of patients with GBV-C/HGV infection: Specific mutational patterns, clinical outcome, and genetic diversity. Journal of Medical Virology, 2000, 62, 191-198.	5.0	12
158	HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. Journal of Hepatology, 2010, 53, 1022-1028.	3.7	12
159	Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-Î² induction by efficient MAVS cleavage. Journal of Hepatology, 2015, 62, 779-784.	3.7	12
160	Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs. Journal of Steroid Biochemistry and Molecular Biology, 2018, 183, 142-151.	2.5	12
161	Resistanceâ€associated substitutions in patients with chronic hepatitis C virus genotype 4 infection. Journal of Viral Hepatitis, 2020, 27, 974-986.	2.0	12
162	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1â€"3 Infections. Clinical Gastroenterology and Hepatology, 2021, 19, 195-198.e2.	4.4	12

#	Article	IF	Citations
163	Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. Infection, Genetics and Evolution, 2009, 9, 847-852.	2.3	11
164	Dimerization of the hepatitis C virus nonstructural protein 4B depends on the integrity of an aminoterminal basic leucine zipper. Protein Science, 2010, 19, 1327-1336.	7.6	11
165	Impact of Ribavirin on HCV Replicon RNA Decline during Treatment with Interferon-Î± and the Protease Inhibitors Boceprevir or Telaprevir. Antiviral Therapy, 2011, 16, 695-704.	1.0	11
166	Nonâ€invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)â€associated liver disease and sustained virologic response (SVR): 3 years followâ€up of a prospective longitudinal study. Journal of Viral Hepatitis, 2021, 28, 1604-1613.	2.0	11
167	Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis. PLoS ONE, 2013, 8, e71262.	2.5	11
168	Dynamics of CD81 expression on lymphocyte subsets during interferon-Â-based antiviral treatment of patients with chronic hepatitis C. Journal of Leukocyte Biology, 2006, 80, 298-308.	3.3	10
169	Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. Journal of Hepatology, 2008, 49, 339-345.	3.7	10
170	Clinical relevance of the 2â€²â€“5â€²-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. Journal of Hepatology, 2009, 50, 49-58.	3.7	10
171	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. Therapeutic Advances in Gastroenterology, 2017, 10, 609-618.	3.2	10
172	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 2022, 4, 100462.	4.9	10
173	Dynamics of Apoptotic Activity during Antiviral Treatment of Patients with Chronic Hepatitis C. Antiviral Therapy, 2007, 12, 779-787.	1.0	10
174	SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. Journal of Hepatology, 2019, 70, 603-614.	3.7	9
175	The hepatitis C virus NS5A protein and response to interferon Î±: mutational analyses in patients with chronic HCV genotype 3a infection from India. Medical Microbiology and Immunology, 2007, 196, 11-21.	4.8	8
176	Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. PLoS ONE, 2013, 8, e77530.	2.5	8
177	Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal. Health Science Reports, 2021, 4, e290.	1.5	8
178	Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C. Journal of Hepatology, 2005, 42, 605-606.	3.7	7
179	Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir. Journal of Clinical Virology, 2015, 72, 133-140.	3.1	7
180	Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. Journal of Infection and Chemotherapy, 2018, 24, 524-530.	1.7	7

#	Article	IF	Citations
181	Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapy. Clinical and Experimental Hepatology, 2018, 4, 83-90.	1.3	7
182	Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-NaÃ¯ve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS ONE, 2017, 12, e0168713.	2.5	6
183	Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection. PLoS ONE, 2018, 13, e0207293.	2.5	6
184	Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis Câ€Registry. Hepatology Communications, 2022, 6, 2488-2495.	4.3	6
185	Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. Hepatology Research, 2005, 31, 18-23.	3.4	5
186	Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 285-294.e1.	4.5	5
187	Management of HCV-Associated Liver Cirrhosis. Visceral Medicine, 2016, 32, 96-104.	1.3	5
188	Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. Scientific Reports, 2016, 6, 35410.	3.3	5
189	Hepatitis C virus genotype 1 and 2 recombinant genomes and the phylogeographic history of the 2k/1b lineage. Virus Evolution, 2019, 5, vez041.	4.9	5
190	Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. Journal of Clinical Microbiology, 2019, 57, .	3.9	5
191	Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. Journal of Clinical Medicine, 2019, 8, 2101.	2.4	5
192	Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy â€“ data from theÂGerman hepatitis C registry (DHC-R). Zeitschrift Fur Gastroenterologie, 2020, 58, 341-351.	0.5	5
193	Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy. PLoS ONE, 2016, 11, e0156731.	2.5	5
194	Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir. PLoS ONE, 2016, 11, e0160668.	2.5	5
195	No Distal Migration in Unfixed Versus Fixed Cell Structure Covered Self-Expanding Metal Stents for Treatment of Benign Biliary Disease. Digestive Diseases and Sciences, 2015, 60, 2495-2501.	2.3	4
196	Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. Liver International, 2015, 35, 176-183.	3.9	4
197	An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-NaÃ¯ve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). PLoS ONE, 2016, 11, e0158526.	2.5	4
198	Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure ofÂprevious direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). Zeitschrift Fur Gastroenterologie, 2020, 58, 841-846.	0.5	4

#	Article	IF	Citations
199	CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology, 2011, 46, 973-980.	1.5	3
200	Viral kinetics for individualized treatment durations. Journal of Hepatology, 2011, 54, 836-837.	3.7	3
201	Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection. Clinical Infectious Diseases, 2011, 53, 1111-1114.	5.8	3
202	HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a. Scandinavian Journal of Gastroenterology, 2011, 46, 1362-1368.	1.5	3
203	HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. Clinical and Experimental Gastroenterology, 2016, Volume 9, 351-363.	2.3	3
204	Treatment of chronic hepatitis C. Journal of Hepatology, 2018, 69, 544-546.	3.7	3
205	PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure. Journal of Hepatology, 2019, 70, e111.	3.7	3
206	Point Shearâ€Wave Elastography Using Acoustic Radiation Force Impulse Imaging for the Prediction of Liverâ€Related Events in Patients With Chronic Viral Hepatitis. Hepatology Communications, 2021, 5, 112-121.	4.3	3
207	Not uncommon: HBV genotype G coâ€infections among healthy European HBV carriers with genotype A and E infection. Liver International, 2021, 41, 1278-1289.	3.9	3
208	Evaluation of Angiotensinogen c.1-44G>A and p.M268T Variants as Risk Factors for Fibrosis Progression in Chronic Hepatitis C and Liver Diseases of Various Etiologies. Genetic Testing and Molecular Biomarkers, 2009, 13, 407-414.	0.7	2
209	Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. Annals of Hepatology, 2013, 12, 190-198.	1.5	2
210	Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection. Journal of Clinical Virology, 2014, 59, 148-155.	3.1	2
211	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS ONE, 2015, 10, e0145622.	2.5	2
212	Relationship between vitamin D status and response to hepatitis C virus therapy. Hepatology, 2015, 62, 1642-1643.	7.3	2
213	Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection. Virology, 2015, 485, 213-222.	2.4	2
214	HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment. PLoS ONE, 2016, 11, e0168544.	2.5	2
215	Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistanceâ€associated substitutions. Liver International, 2020, 40, 2660-2671.	3.9	2
216	Late presentation of chronic hepatitis C patients in the era of directâ€acting antiviralsâ€”Data from the German Hepatitis Câ€Registry. Journal of Viral Hepatitis, 2021, 28, 1660-1664.	2.0	2

#	Article	IF	Citations
217	Epistatic interactions promote persistence of NS3-Q80K inÂHCV infection by compensating for protein folding instability. Journal of Biological Chemistry, 2021, 297, 101031.	3.4	2
218	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. JCI Insight, 2020, 5, .	5.0	2
219	Early occurrence of hepatocellular carcinoma in patients with and without cirrhosis after HCV treatment with direct-acting antivirals.. Journal of Clinical Oncology, 2018, 36, 356-356.	1.6	2
220	Diagnosis of hepatitis C: update 2004. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, S88-S93.	2.8	1
221	Reply to Real-Time Elastography in the Assessment of Liver Fibrosis. American Journal of Roentgenology, 2008, 190, W164-W164.	2.2	1
222	Viral Infections by Hepatotropic Viruses. , 2010, , 671-821.		1
223	Reply to â€œVitamin D deficiency and HCV chronic infection: What comes first?â€• Journal of Hepatology, 2011, 55, 945.	3.7	1
224	Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C. Antiviral Therapy, 2013, 18, 803-811.	1.0	1
225	Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy. PLoS ONE, 2019, 14, e0224751.	2.5	1
226	Reply to: â€œGlecaprevir/pibrentasvirÂ+ sofosbuvirÂ+ ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settingsâ€• Journal of Hepatology, 2021, 75, 254-255.	3.7	1
227	Virologische und immunologische Grundlagen der Therapie der chronischen HCV-Infektion. Suchttherapie, 2002, 3, S37-S44.	0.1	0
228	Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection. Scandinavian Journal of Gastroenterology, 2014, 49, 1473-1479.	1.5	0
229	Reply to: â€œEvidence supporting a beneficial role of vitamin D in chronic hepatitis Câ€• Journal of Hepatology, 2015, 63, 531-532.	3.7	0
230	Reply to: â€œHCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirinâ€• Journal of Hepatology, 2016, 65, 1059-1060.	3.7	0
231	Reply. Hepatology, 2016, 64, 1378-1379.	7.3	0
232	Protease Inhibitor Resistance. , 2017, , 21-40.		0
233	Protease Inhibitor Resistance. , 2015, , 1-17.		0